...analyst at Davy, which acts as stockbroker to Elan, said the detailed presentation on the new medicine provided as many questions as answers but the stock price reaction looked overdone. (Reporting by
Ben Hirschler; Editing by Erica Billingham)
By: Ben Hirschler|Date: Jul 30, 2008